Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

PekCura Labs

Has PekCura Labs received an FDA warning letter? Yes. FDA issued a warning letter dated March 31, 2026.

Letter facts

Letter date
March 31, 2026 (2026-03-31)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Online / Internet Pharmacy
Products named
GLP-1-S (all variations)GLP-2-T (all variations)GLP-3-R (all variations)Bacteriostatic Water (all variations)Cag (1mg) Tirz (10mg) Blend
Violation categories
Unapproved new drug

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Factual Violation Summary

FDA determined PekCura Labs' GLP-1-S, GLP-2-T, GLP-3-R, and Bacteriostatic Water are unapproved new drugs intended for human use; no approved applications are in effect, violating FD&C Act sections 505(a) and 301(d).

Statutory Citations & Specific Allegations

  • Unapproved new drugs

More letters about Retatrutide

Recent FDA warning letters concerning Retatrutide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.